A few weeks ago, doctors had sent a letter to the Minister of Health in which they drew her attention to three oral anticoagulants (Eliquis, Pradaxa and Xarelo) that insisting that “the new oral anticoagulants ( NACO) are the “new Mediator “And that France is close to a new medical scandal”.
The oral anticoagulants in question appeared in France 5 years ago and are prescribed to prevent phlebitis, embolism and certain cardiovascular disorders (heart attacks and strokes). Gradually, these new oral anticoagulants (NOACs) replaced the drugs of the older generation (antivitamin K or AVK) because they require less regular monitoring. But the problem, according to biologists, is that these drugs cause serious side effects (severe bleeding, even fatal) for which there is, for the moment, no antidote. Clearly, if there is a bleeding, the doctors have no way of stopping it.
It was these hemorrhagic accidents that caused the death of four patients aged 78 to 84 from Lille, Strasbourg, Paris and Grenoble at the start of the year. The families of these deceased patients have therefore decided to file a complaint against Boehringer Ingelheim, the German laboratory which markets the drug and also to turn against the National Agency for the Safety of Medicines and Health Products (ANSM) for having disregarded the principles. precaution and prevention.
On his website, the ANSM underlines that “the NACOs are subject to close and regular surveillance at national level by the ANSM and at European level by the European health authorities. “In France, national pharmacovigilance monitoring has been put in place since the marketing of these specialties. A progress report will be made by the Pharmacovigilance Technical Committee in November 2013 concerning Pradaxa and Xarelto following the reviews already carried out in July 2010 and February 2013. At the end of this pharmacovigilance review, the ANSM will be required to communicate on the conclusions of this monitoring and will update the thematic report on anticoagulants of July 2012. ”
